Keywords
How to Cite
Abstract
Investigation of the properties of the oral liquid and polymorphism of the MUC5B gene in children with cystic fibrosis
Nazaryan R., Tkachenko M.,Volkova N.
The article presents the study of biophysical and biochemical properties of saliva and polymorphism of the MUC5B protein gene in children with cystic fibrosis. It has been determined that the development of chronic gingivitis in children with cystic fibrosis occurs of the background of a saliva elasticity increasing and of the salivation rate decreasing. The presence of the allele of MUC5B gene with 9 repeats (59 bp) in the intron 36 in the genotype for cystic fibrosis patients is likely to indicate a lower tendency to gingivitis, while among patients possessing the allele with 6 repeats in the genotype the higher percentage of moderately severe gingivitis was detected. These data could be used to predict the development of chronic gingivitis, depending on the genetic polymorphism of the MUC5B gene and to form risk groups for the purpose of differentiated prescribing preventive and therapeutic measures.
Keywords: children, cystic fibrosis, gene polymorphism, gingivitis, oral fluid.
Резюме.
ДОСЛІДЖЕННЯ ВЛАСТИВОСТЕЙ РОТОВОЇ РІДИНИ І ПОЛІМОРФІЗМУ ГЕНУ MUC5B У ХВОРИХ НА МУКОВІСЦИДОЗ ДІТЕЙ
Назарян Р. С., Ткаченко М. В., Волкова Н. Є.
Проведено дослідження біофізичних та біохімічних властивостей ротової рідини та поліморфізму гена білка MUC5B у хворих на муковісцидоз дітей. Визначено, що розвиток хронічного гінгівіту у дітей з муковісцидозом відбувається на тлі підвищення показників тягучості ротової рідини та зниження швидкості слиновиділення. Алельні варіанти кількості повторів 59 п.н. у інтроні 36 гена MUC5B можуть вказувати на схильність пацієнтів до розвитку різного ступеню тяжкості гінгівіту. Результати дослідження можуть бути використані з діагностичною та прогностичною метою і диференційованого призначення профілактичних та лікувальних заходів.
Ключові слова: гінгівіт, діти, муковісцидоз, поліморфізм генів, ротова рідина.
Резюме.
ИССЛЕДОВАНИЕ СВОЙСТВ РОТОВОЙ ЖИДКОСТИ И ПОЛИМОРФИЗМА ГЕНА MUC5B У БОЛЬНЫХ МУКОВИСЦИДОЗОМ ДЕТЕЙ
Назарян Р. С., Ткаченко М.В., Волкова Н. Е.
Проведено исследование биофизических и биохимических свойств ротовой жидкости и полиморфизма гена белка MUC5B у больных муковисцидозом детей. Определено, что развитие хронического гингивита у детей с муковисцидозом происходит на фоне повышения показателей тягучести ротовой жидкости и снижения скорости слюноотделения. Аллельные варианты количества повторов 59 п.н. в интроне 36 гена MUC5B могут указывать на склонность пациентов к развитию гингивита различной степени тяжести. Результаты исследования могут быть использованы с диагностической и прогностической целью и дифференцированного назначения профилактических и лечебных мероприятий.
Ключевые слова: гингивит, дети, муковисцидоз, полиморфизм генов, ротовая жидкость.
References
References:
Kazakova, R.V., Mel'nik, V.S. (2013). Vzaєmozv’yazok zapal'nih zahvoryuvan' parodonta і patologії organіv travlennya u dіtej і pіdlіtkіv [Interconnection of inflammatory diseases of periodontal disease and pathology of digestive organs in children and adolescents]. Naukovij vіsnik Uzhgorods'kogo unіversitetu, 2 (47),150-4.
Gumenyuk, M.І., Mazur, І.P., Іgnat'єva, V.І., Harchenko–Sevryukova, G.S. (2015). Osoblivostі klіnіchnih proyavіv patologіchnih procesіv parodonta u hvorih na hronіchne obstruktivne zahvoryuvannya legen' [Features of clinical manifestations of pathological processes of periodontis in patients with chronic obstructive pulmonary disease]. Ukraїns'kij pul'monologіchnij zhurnal, 1,40-4.
Grechanina, E.YA., Grechanina, YU.B., YAnovskaya, A.A. (2014). ZHeludochno-kishechnye i metabolicheskie narusheniya pri mukoviscidoze [Gastrointestinal and metabolic disorders in cystic fibrosis]. Lіkar. Sprava,11,149-54.
Baranov, A.A., editor (2009). Klinicheskie Rekomendacii. Pediatriya [Clinical Recommendations. Pediatrics]. Soyuz Pediatrov Rossii. 2–e izd. Moscow:GEHOTAR–Media, 432 p.
Klyarits'ka, І.L., Moshko, YU.A. (2010). Gastroenterologіchnі problemi mukovіscidozu [Gastroenterologic problems of cystic fibrosis]. Krims'kij terapevtichnij zhurnal, 2, 37-41.
Kapranov, N.I., Kashirskaya, N.YU., editors (2014). Mukoviscidoz [Cystic Fibrosis]. Moscow:ID «Medpraktika-M», 672 p.
Nakaz Mіnіsterstva ohoroni zdorov’ya Ukraїni № 723 (15.07.2016) «Pro zatverdzhennya ta vprovadzhennya mediko–tekhnologіchnih dokumentіv zі standartizacії medichnoї dopomogi pri mukovіscidozі» [Order of the Ministry of Health of Ukraine No. 723 (15.07.2016) "On approval and implementation of medical-technological documents on standardization of medical aid in cystic fibrosis]. Retrieved : http://www.moz.gov.ua/ua/portal/dn_20160715_0723.html.
Orlov, A.V., Simonova, O.I., Roslavceva, E.A., SHadrin, D.I. (2014). Mukoviscidoz (klinicheskaya kartina, diagnostika, lechenie, reabilitaciya, dispanserizaciya): uchebnoe posobie dlya vrachej [Cystic fibrosis (clinical picture, diagnosis, treatment, rehabilitation, clinical examination): a training manual for doctors]. Sankt-Peterburg: Izd-vo SZGMU im. I. I. Mechnikova,160 p.: il.
Patel, R.M., Varma, S., Suragimath, G., Zope, S. (2016). Estimation and Comparison of Salivary Calcium, Phosphorous, Alkaline Phosphatase and pH Levels in Periodontal Health and Disease: A Cross–sectional Biochemical Study. J Clin Diagn Res, 10(7), 58-61.
Alexander, S. (2014). Clinical Guidelines: Care of Children with Cystic Fibrosis. Royal Brompton Hospital. Endorsed by the Medicines Management Board of Royal Brompton & Harefield NHS Foundation Trust.,The 6th edition. Available from: https://www.rbht.nhs.uk/our-services.
Smyth, A.R., Scott, C., Bojcin, S., Bryon, M. et al. (2014). European Cystic Fibrosis Society Standards of Care: Best Practice Guidelines. Journal of Cystic Fibrosis, 13, 23-42.
Leus, P.A. (2011). Diagnosticheskoe znachenie gomeostaza slyuny v klinike terapevticheskoj stomatologii : ucheb.–metod. posobie [Diagnostic value of saliva homeostasis in the clinic of therapeutic dentistry: prac. - method. allowance]. Minsk: BGMU, 67 p.
Carev, V.N., editor. (2013). Mikrobiologiya, virusologiya i immunologiya polosti rta : ucheb [Microbiology, virology and immunology of the oral cavity: studies]. Moscow: GEHOTAR–Media, 576 p.: il.
Aken, B.L., Ayling, S., Barrell, D., Clarke, L. et al. (2016). The Ensembl gene annotation system. doi: 10.1093/database/baw093.
Mattila, K.J., Pussinen, P.J., Paju S. (2005). Dental Infections And Cardiovascular Diseases: A Review. J. Periodontol, 76, 2085-2088. doi:10.1902/jop.2005.76.11-S.2085.
Rose, M.C., Voynow, J.A. (2006). Respiratory Tract Mucin Genes And Mucin Glycoproteins In Health And Disease. Physiol Rev, 86, 245-78.
Desseyn, J-L., Rousseau, K., Laine, A. (1999). Fifty-nine bp Repeat Polymorphism In The Uncommon Intron 36 Of The Human Mucin Gene MUC5B. Electrophoresis, 20, 493-6.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.